Clinical Trial

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this phase II is to study the efficacy and toxicity of carboplatin and paclitaxel with pertuzumab and trastuzumab in HER2 positive and carboplatin and paclitaxel with bevacizumab in HER2 negative in the neoadjuvant setting for the treatment of breast cancer.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2015-05-04; most recent amendment 2025-07-10.
Status change: Recruiting → Active, Not Recruiting 2023-06-30
Trial Details
NCT Number NCT02436993
Lead Sponsor University of California, Irvine
Conditions Breast Carcinoma
Enrollment 120 participants
Start Date 2015-04
Primary Completion 2023-11 (estimated)
Study Completion 2036-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-14